NCT06374264
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
Enrolling by Invitation
NAAges 18–70InterventionalTreatmentMedRhythms, Inc.
~30 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:MR-C-014
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Participant acceptability of MR-C-014
Measured over Intervention period (of up to 8 weeks)
+1 more outcome measured
Conditions
Where it's being run
2 sites across 2 statesGeorgia1
Massachusetts1
Study leadership
- Eric Klawiter, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Participant acceptability of MR-C-014Intervention period (of up to 8 weeks)
Assesses participant engagement via logged use of MR-C-014
- Number of device-related adverse events (AEs)Weekly for up to 8 weeks
Assesses the safety of MR-C-014 in NMOSD patients with a gait deficit